AN2 Therapeutics Inc (ANTX)
2.27
0.00 (0.00%)
USD |
NASDAQ |
May 16, 16:00
2.255
-0.02
(-0.66%)
After-Hours: 20:00
AN2 Therapeutics Cash from Financing (Quarterly): 0.349M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.349M |
| December 31, 2023 | -0.321M |
| September 30, 2023 | 66.07M |
| June 30, 2023 | 19.05M |
| March 31, 2023 | 0.199M |
| December 31, 2022 | 0.00 |
| September 30, 2022 | -0.01M |
| Date | Value |
|---|---|
| June 30, 2022 | 7.178M |
| March 31, 2022 | 63.19M |
| December 31, 2021 | -0.969M |
| September 30, 2021 | -0.24M |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 79.74M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.969M
Minimum
Dec 2021
79.74M
Maximum
Mar 2021
18.02M
Average
0.199M
Median
Mar 2023
Cash from Financing (Quarterly) Benchmarks
| Gilead Sciences Inc | -1.361B |
| QuidelOrtho Corp | -18.50M |
| CymaBay Therapeutics Inc (DELISTED) | 2.729M |
| Insmed Inc | 3.022M |
| Revance Therapeutics Inc | 92.83M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -17.59M |
| Cash from Investing (Quarterly) | 26.29M |
| Free Cash Flow | -59.28M |
| Free Cash Flow Per Share (Quarterly) | -0.5911 |
| Free Cash Flow Yield | -99.77% |